1 April 2026 in RETINAL Cases & Brief Reports
Purpose: To report a case of choroidal neovascularization in a patient with gestational hypertension using optical coherence tomography angiography (OCT-A). Methods: This is a case report. Results: A 32-year-old woman with gestational hypertension without pre-eclampsia presented with new choroidal neovascularization two months postpartum (visual acuity of 20/70). Subretinal hemorrhage resolved after injection of intravitreal bevacizumab, and regression of choroidal neovascularization was visualized by optical coherence tomography angiography. Treatment was repeated 7 months later for recurrence of hemorrhage, and she remained stable with visual acuity of 20/20 at 12-month follow-up. Conclusion: Practitioners should be aware that patients with gestational hypertension may develop delayed and visually significant choroidal neovascularization. Optical coherence tomography angiography serves as a valuable, noninvasive tool for diagnosis and follow-up in this population. Early recognition and prompt treatment can lead to favorable visual outcomes.
23 October 2026 in American Journal of Ophthalmology Case Reports
1 January 2026 in Case Reports in Oncological Medicine
Background: Pulmonary NUT carcinoma is a rare but highly aggressive malignancy with poor prognosis. It typically affects younger patients with no smoking history. Given its rapid progression, it is crucial to consider it as a differential diagnosis in a poorly differentiated thoracic mass to ensure timely diagnosis and management. Case Presentation: We report a case of primary pulmonary NUT carcinoma diagnosed in a 59‐year‐old male with a never‐smoking history during routine screening for possible occupational asbestos exposure. The preliminary diagnosis of metastatic keratinizing squamous cell carcinoma was later reclassified as NUT carcinoma by immunohistochemistry. Next generation sequencing of ctDNA showed CDKN2A mutation. The therapeutic course was complicated by several hypersensitivity reactions to first line treatments. Due to rapidly deteriorating clinical status, the patient was no longer eligible for a BET inhibitor clinical trial and died approximately 5 months after diagnosis. Conclusion: Due to its rarity and poor therapeutic response, there is currently no established standard of treatment for pulmonary NUT carcinoma. Timely and accurate diagnosis remains challenging due to its nonspecific presentation and rarity, resulting in low clinical suspicion, especially in patients outside the typical demographic. Common first‐line treatments include platinum‐based regimens in combination with etoposide or paclitaxel. Several clinical trials of BET and histone deacetylase inhibitors are active, and clinicians are encouraged to enroll patients to maximize survival outcomes.